File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Liver transplantation for hepatocellular carcinoma

TitleLiver transplantation for hepatocellular carcinoma
Authors
KeywordsHepatocellular
Hepatoma
Transplantation
Issue Date2008
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
Citation
Annals Of Surgical Oncology, 2008, v. 15 n. 4, p. 1001-1007 How to Cite?
AbstractBackground: Orthotopic liver transplantation (OLT) is the best available option for early hepatocellular carcinoma (HCC), although its application is limited by stringent selection criteria, costs, and deceased donor graft shortage, particularly in Asia, where living donor liver transplant (LDLT) has been developed. Methods: This article reviews the present standards for patient selection represented by size-and-number criteria with particular references to Milan Criteria and novel prediction models based on results achieved in patients exceeding those limits, with consideration of the expanded indication represented by the UCSF Criteria. Results: The expected outcomes after deceased donor liver transplant (DDLT) or LDLT are favorable if predetermined selection criteria are applied. However, selection bias, difference in waiting time, and ischemia-regeneration injuries of the graft among DDLT vs LDLT may influence long-term results. In the article, the differences between East and West in first-line treatments for HCC (resection vs transplantation), indications, and ethics for the donor, are summarized as well as possible novel predictors of tumor biology (especially DNA mutation and fractional allelic loss, FAI) to be considered for better outcome prediction. Conclusions: Liver transplantation remains the most promising product of modern surgery and represents a cornerstone in the management of patients with HCC. © 2007 The Author(s).
Persistent Identifierhttp://hdl.handle.net/10722/147096
ISSN
2014 Impact Factor: 3.930
2014 SCImago Journal Rankings: 1.812
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMazzaferro, Ven_HK
dc.contributor.authorChun, YSen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorSchwartz, MEen_HK
dc.contributor.authorYao, FYen_HK
dc.contributor.authorMarsh, JWen_HK
dc.contributor.authorBhoori, Sen_HK
dc.contributor.authorLee, SGen_HK
dc.date.accessioned2012-05-25T07:50:40Z-
dc.date.available2012-05-25T07:50:40Z-
dc.date.issued2008en_HK
dc.identifier.citationAnnals Of Surgical Oncology, 2008, v. 15 n. 4, p. 1001-1007en_HK
dc.identifier.issn1068-9265en_HK
dc.identifier.urihttp://hdl.handle.net/10722/147096-
dc.description.abstractBackground: Orthotopic liver transplantation (OLT) is the best available option for early hepatocellular carcinoma (HCC), although its application is limited by stringent selection criteria, costs, and deceased donor graft shortage, particularly in Asia, where living donor liver transplant (LDLT) has been developed. Methods: This article reviews the present standards for patient selection represented by size-and-number criteria with particular references to Milan Criteria and novel prediction models based on results achieved in patients exceeding those limits, with consideration of the expanded indication represented by the UCSF Criteria. Results: The expected outcomes after deceased donor liver transplant (DDLT) or LDLT are favorable if predetermined selection criteria are applied. However, selection bias, difference in waiting time, and ischemia-regeneration injuries of the graft among DDLT vs LDLT may influence long-term results. In the article, the differences between East and West in first-line treatments for HCC (resection vs transplantation), indications, and ethics for the donor, are summarized as well as possible novel predictors of tumor biology (especially DNA mutation and fractional allelic loss, FAI) to be considered for better outcome prediction. Conclusions: Liver transplantation remains the most promising product of modern surgery and represents a cornerstone in the management of patients with HCC. © 2007 The Author(s).en_HK
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.orgen_HK
dc.relation.ispartofAnnals of Surgical Oncologyen_HK
dc.rightsSpringer New Yorken_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.subjectHepatocellularen_HK
dc.subjectHepatomaen_HK
dc.subjectTransplantationen_HK
dc.titleLiver transplantation for hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://www.springerlink.com/link-out/?id=2104&code=Y6717521028L7817&MUD=MPen_US
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1245/s10434-007-9559-5en_HK
dc.identifier.pmid18236119en_HK
dc.identifier.scopuseid_2-s2.0-40549119470en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40549119470&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue4en_HK
dc.identifier.spage1001en_HK
dc.identifier.epage1007en_HK
dc.identifier.eissn1534-4681en_US
dc.identifier.isiWOS:000253896000009-
dc.publisher.placeUnited Statesen_HK
dc.description.otherSpringer Open Choice, 25 May 2012en_US
dc.identifier.scopusauthoridMazzaferro, V=7006292400en_HK
dc.identifier.scopusauthoridChun, YS=22633742400en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridSchwartz, ME=7404649084en_HK
dc.identifier.scopusauthoridYao, FY=7102637912en_HK
dc.identifier.scopusauthoridMarsh, JW=35369954700en_HK
dc.identifier.scopusauthoridBhoori, S=23479552000en_HK
dc.identifier.scopusauthoridLee, SG=7601404245en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats